about
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study.Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients.Multimodal In Vivo Imaging of Tumorigenesis and Response to Chemotherapy in a Transgenic Mouse Model of Mammary CancerInfluence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer.The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.Platination of telomeric DNA by cisplatin disrupts recognition by TRF2 and TRF1.Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients.Continuation of high-dose vancomycin despite nephrotoxicity.Influence of ABCB1 polymorphisms and docetaxel pharmacokinetics on pathological response to neoadjuvant chemotherapy in breast cancer patients.Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.P08.63 Dose optimization of MK-8628 (OTX015), a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins, in patients with recurrent glioblastoma.A single-dose PK study of onapristone including the effect of food on absorption.Extracellular Adenosine Triphosphate Affects the Response of Human Macrophages Infected With Mycobacterium tuberculosisPhase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancersBET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistancePharmacokinetics, metabolism, and routes of excretion of intravenous irofulven in patients with advanced solid tumorsA phase I trial combining oral cisplatin (CP Ethypharm) with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma[Adaptation of methotrexate determination in serum with Unicel DxC600(®)]Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignanciesSevere docetaxel overdose induced by pharmacokinetic interaction with dronedaronePhase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid TumorsCyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP
P50
Q33431391-B290E5B3-394C-4E01-B6AA-A84A4DEA89B1Q34046624-194FACAD-2189-4EAD-B9E1-D39FEF3DF8D9Q34129436-88673226-58A3-4E05-9337-B0F36C53D41EQ34503914-87179941-0137-4686-BAE7-35277EC835C1Q36806664-F94B82C5-3433-41AD-BB9B-75A2B05C67D2Q37702577-E95E9B5A-EC60-4405-A69D-C39C9F59DDC9Q37705651-CEC4E469-D023-41BB-81D3-9F7C524B5B42Q39520264-F45BD72D-5C6A-4641-A8AE-F84C95B3B970Q39733900-35BA06CD-CD5A-40BD-9287-F4F62A626C42Q42598708-E5DF4C81-EE17-420F-8984-0EC47EC3CD71Q43193998-E1B4CB15-FB6B-4B45-A4D9-61CDE0B52781Q45701181-09FB4687-A0FF-4C4B-9338-6B3E9385D4FCQ46801585-365EE74F-B05F-465E-9872-75A6C9056AD3Q47741271-B062F751-1924-4B58-B0F7-ED40C9F303FBQ50348679-E5659AB2-82A5-4877-968E-3C0E0E89D883Q51022135-01D6275E-7305-4E91-B074-652508038C84Q57029003-5D632E3C-FE55-4F16-A9B9-222ED36B4654Q57286101-C373C3C4-4213-4F53-A8FD-941FCB7FDD14Q57299887-ADDF5A13-B449-4FD0-909D-4CDAB8E9B209Q80077547-7CFEC363-0CD1-4BD7-BB0B-B23B372ECA1DQ82989573-822DACCB-A385-4BFF-B460-21B4A21E8EBAQ84078906-19F5FB65-BE1B-4596-A83C-F192A0554751Q84314377-D09C2C41-5CC9-4DB0-B93E-29F77488FC59Q84509642-F22D4324-96C2-4C3C-A80E-7F2497BF6434Q88590263-F966B922-D0AF-402A-9776-D23FFF78F715Q91248728-259AFB8A-A032-446E-81EE-9DB17600CED8
P50
description
researcher ORCID ID = 0000-0002-3328-3102
@en
wetenschapper
@nl
name
Keyvan Rezai
@ast
Keyvan Rezai
@en
Keyvan Rezai
@es
Keyvan Rezai
@nl
type
label
Keyvan Rezai
@ast
Keyvan Rezai
@en
Keyvan Rezai
@es
Keyvan Rezai
@nl
prefLabel
Keyvan Rezai
@ast
Keyvan Rezai
@en
Keyvan Rezai
@es
Keyvan Rezai
@nl
P108
P31
P496
0000-0002-3328-3102